Venus Medtech (Hangzhou) Inc. and Jilin Changchun Haoyue Halal Meat Co. Ltd. (Haoyue Group), announced the establishment of a joint venture company, Venus HaoyueMedtech Limited (Venus Haoyue Medtech). Venus Medtech and Venus Haoyue Medtech will jointly provide total treatment solutions for heart valve diseases from the source of biomaterials. It will become a domestic enterprise with both surgical valves and transcatheter valves, which will comprehensively improve the level of heart valve diseases treatment in China. Venus Haoyue Medtech will be engaged in the design, research and development, manufacturing, sales, and technical services of high-end cardiovascular disease implant devices and surgical soft tissue repair materials. The main products are artificial biological heart valves for surgical implantation and other biological patches. Venus Haoyue Medtech develops surgical valve products including aortic, pulmonary, mitral and tricuspid valves. Venus Medtech will also cooperate with NERCB to inject the most advanced engineered dry valve technology into Venus Haoyue Medtech, in order to upgrade all newly developed surgical valves and biological patch products and optimize product research development to create more clinical benefits. The application of engineered dry valve technology in surgical valves will raise the standard of research and development of valve products and provide new treatment options. Professor Meng Xu also expressed his high expectation and recognition of the dry valve technology and emphasized the importance of these breakthrough technologies in the field of heart valve treatment.